Work

AML-112: Revumenib Activity in Patients With Acute Leukemia With NUP98r: Results From the AUGMENT-101 Phase 1 Study

Year: 2025

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)01624-6

Authors: Ghayas C. Issa, Branko Cuglievan, John F. DiPersio, Li Yu, Sharda Jha, Angela R. Smith, Eytan M. Stein

Institutions: The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Syndax Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413782888

Cites:

Cited by: 2

Related to: 10